Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

NCT02556463 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02556463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02556463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Terminated
Start date
November 4, 2015
Completion date
October 26, 2018
Enrollment
53 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, ctcl, solid tumors